James E Talmadge
Overview
Explore the profile of James E Talmadge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poole J, Cole K, Thiele G, Talmadge J, England B, Nelson A, et al.
Int Immunopharmacol
. 2023 Dec;
127():111330.
PMID: 38086271
Objectives: Interstitial lung disease (ILD) is associated with significant mortality in rheumatoid arthritis (RA) patients with key cellular players remaining largely unknown. This study aimed to characterize inflammatory and myeloid...
2.
Khadge S, Thiele G, Sharp J, McGuire T, Klassen L, Black P, et al.
Clin Exp Metastasis
. 2023 Aug;
40(5):441.
PMID: 37535129
No abstract available.
3.
Cole K, Al-Kadhimi Z, Talmadge J
Int Immunopharmacol
. 2023 Feb;
117:109882.
PMID: 36848790
Immunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field...
4.
Cole K, Al-Kadhimi Z, Talmadge J
Cancer Metastasis Rev
. 2023 Jan;
42(1):113-142.
PMID: 36640224
The establishment of primary tumor cells in distant organs, termed metastasis, is the principal cause of cancer mortality and is a crucial therapeutic target in oncology. Thus, it is critical...
5.
Cole K, Ly Q, Hollingsworth M, Cox J, Fisher K, Padussis J, et al.
Int Immunopharmacol
. 2022 Feb;
106:108628.
PMID: 35203041
In recent years, immune therapy, notably immune checkpoint inhibitors (ICI), in conjunction with chemotherapy and surgery has demonstrated therapeutic activity for some tumor types. However, little is known about the...
6.
Britton H, Draper M, Talmadge J
Infect Prev Pract
. 2021 Aug;
2(1):100032.
PMID: 34368688
Background: Mitigating surface contamination by microbes such as , , or , is an ongoing problem in hospital and food production environments. Aim: To determine whether addition of buffering solution...
7.
Khadge S, Cole K, Talmadge J
Clin Exp Metastasis
. 2021 May;
38(3):279-293.
PMID: 34014424
Metastasis is the primary cause of cancer mortality and an improved understanding of its pathology is critical to the development of novel therapeutic approaches. Mechanism-based therapeutic strategies require insight into...
8.
Talmadge J, Marceau F
Int Immunopharmacol
. 2021 Mar;
95:107543.
PMID: 33735717
No abstract available.
9.
Cole K, Ly Q, Hollingsworth M, Cox J, Padussis J, Foster J, et al.
Cell Immunol
. 2021 Mar;
363:104317.
PMID: 33714729
Myeloid derived suppressor cells (MDSCs) can be subset into monocytic (M-), granulocytic (G-) or polymorphonuclear (PMN-), and immature (i-) or early MDSCs and have a role in many disease states....
10.
Cole K, Pravoverov K, Talmadge J
Cancer Metastasis Rev
. 2021 Jan;
40(2):391-411.
PMID: 33411082
The spread of primary tumor cells to distant organs, termed metastasis, is the principal cause of cancer mortality and is a critical therapeutic target in oncology. Thus, a better understanding...